Folotyn (Pralatrexate) for Lymphoma | MyLymphomaTeam

Connect with others who understand.

sign up Log in
About MyLymphomaTeam
Powered By

Folotyn is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat peripheral T-cell lymphoma (PTCL) that has relapsed or failed to respond to other drugs. Folotyn is also referred to by its drug name, pralatrexate.

Folotyn is an anticancer drug. Folotyn is an antifolate and an antimetabolite. Folotyn is believed to work by killing cancer cells and slowing their growth.

How do I take it?
Folotyn is administered by intravenous injection once a week for six weeks.

Folotyn comes in the form of a single-dose vial.

Side effects
The FDA-approved label for Folotyn lists common side effects including fever, fatigue, nausea, dehydration, trouble breathing, low blood cell counts, and mucositis – inflammation of the mucous membranes that line the gastrointestinal tract.

Rare but serious side effects listed for Folotyn include sepsis (life-threatening reaction to infection), liver damage, fetal harm in pregnant women, severe skin reactions, and tumor lysis syndrome (a potentially fatal metabolic condition caused when many cancer cells die at the same time).

For more details about this treatment, visit:

Folotyn — Acrotech Biopharma

Treatment for Aggressive NHL Subtypes — Leukemia & Lymphoma Society

Continue with Facebook
Continue with Google
Lock Icon Your privacy is our priority. By continuing, you accept our Terms of use, and our Health Data and Privacy policies.
Already a Member? Log in